Press Release: DIAFIR announces the acceptance of an abstract at The Liver Meeting Digital Experience™ 2020

RENNES, FRANCE— November 04, 2020

DIAFIR, a medical technology company focused on the development, manufacture and sale of innovative diagnostic solutions, today announced that an abstract has been selected for poster presentation during the upcoming The Liver Meeting Digital Experience™ 2020, organized by the American Association for the Study of Liver Disease (AASLD) on November 13-16, 2020.

The abstract covers new data, in collaboration with University Hospital of Nice, France, evaluating the diagnostic performance of Diafir’s NASH blood-based test, focusing in type-2 diabetic (TD2M) severely obese patients.

The details of the presentation are as follow:

Abstract title:              “Mid-Infrared spectroscopy blood-based test correctly identifies NASH risk in severely obese patients with type 2 diabetes”

Publication number: 1529

Session title:                Poster, Category Index NAFLD and NASH, Diagnostics and Biomarkers

Presentation type:     Poster presentation

Author:                          Prof. Rodolphe Anty, University Hospital Nice, France.

The abstract is featured in the November issue of the scientific journal Hepatology (vol. 72, issue S1) and is available on the website of AASLD (www.tlmdx.aasld.org)

 

ABOUT AASLD

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients. We advance the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.

ABOUT DIAFIR

DIAFIR is a medical technology company with expertise in developing disruptive in vitro diagnostic tests to improve the patient care management. Our technology relies on spectroscopic mid-infrared analysis of the metabolic signature of patients using our SPID™ platform, which allows for low-invasive, cost-effective and rapid diagnostic procedures. DIAFIR is an ISO 13485 company.

Contact DIAFIR :                                                 

Jerome Bernard                       

General Manager Healthcare                                       

info@diafir.com                                                               

+33 (0)2 99 67 15 41                                          

www.diafir.com

Ruling out septic arthritis risk in a few minutes using mid-infrared spectroscopy in synovial fluids. Press Release: DIAFIR announces the acceptance of an abstract at The Liver Meeting Digital Experience™ 2020

Leave a Reply

Your email address will not be published. Required fields are marked *